Business

Around the Region

Biogen’s Hemophilia drug awaits approval

Biogen Idec Inc., the Weston biotechnology company known for its drugs to treat multiple sclerosis drugs, is seeking US regulatory approval for a long-lasting treatment for hemophilia A, a rare inherited disorder that impairs blood clotting.

Current treatments can require a patient to get three or four injections a week. Biogen Idec’s hope is that a patient would need one or two injections per week.

Advertisement

If approved, the treatment would be the first major advance­ for hemophilia A patients­ in more than two decades, the company said.

In a press release, the company said it is seeking Food and Drug Administration approval to the market recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com